Metastatic Prostate Adenocarcinoma Clinical Trials

33 clinical trials for Metastatic Prostate Adenocarcinoma across international registries, including 13 currently recruiting participants. Compare status, phase, eligibility criteria and locations.

• Cell Therapy (STEAP1 CART) With Enzalutamide for the Treatment of Patients With Metastatic Castration-Resistant Prostate Cancer — RECRUITING · PHASE1
• Vorinostat and 177Lu-PSMA-617 for the Treatment of PSMA-Low Metastatic Castration-Resistant Prostate Cancer — RECRUITING · PHASE2
• Testing the Addition of Docetaxel (Chemotherapy) to the Usual Treatment (Hormonal Therapy and Apalutamide) for Metastatic Prostate Cancer, ASPIRE Trial — RECRUITING · PHASE3
• Testing Different Dosing Schedules of the Anti-cancer Drug, Lutetium 177Lu PSMA RLT and Its Effect on Patients With Advanced Prostate Cancer, RECIPROCAL Trial — RECRUITING · PHASE3
• Abemaciclib Before 177Lu-PSMA-617 for the Treatment of Metastatic Castrate Resistant Prostate Cancer — RECRUITING · PHASE1
• Supraphysiological Androgen to Enhance Treatment Activity in Metastatic Castration-Resistant Prostate Cancer, SPECTRA Study — RECRUITING · PHASE2
• Cabozantinib and Atezolizumab for the Treatment of Metastatic Castration-Resistant Prostate Cancer — RECRUITING · PHASE2
• Ruxolitinib and Enzalutamide for the Treatment of Metastatic Castration-Resistant Prostate Cancer — RECRUITING · PHASE1
• Bipolar Androgen Therapy (BAT) and Radium-223 (RAD) in Metastatic Castration-resistant Prostate Cancer (mCRPC) — RECRUITING · PHASE2
• Talazoparib With Androgen Deprivation Therapy and Abiraterone for the Treatment of Castration Sensitive Prostate Cancer — RECRUITING · PHASE2
• Measuring Oncological Value of Exercise and Statin — RECRUITING · PHASE3
• Kuopio Lutetium-177 Study in Patients with PSMA-Positive Metastatic Prostate Cancer — RECRUITING
• Modifying Metabolic Syndrome and Cardiovascular Risk for Prostate Cancer Patients on ADT Using a Risk Factor Modification Program and Continuous Fitbit Monitoring — RECRUITING · PHASE2
• Testing the Safety of Different Doses of Olaparib Given Radium-223 for Men With Advanced Prostate Cancer With Bone Metastasis — ACTIVE_NOT_RECRUITING · PHASE1
• ZEN-3694, Enzalutamide, and Pembrolizumab for the Treatment of Metastatic Castration-Resistant Prostate Cancer — ACTIVE_NOT_RECRUITING · PHASE2
• CJNJ-67652000 and Prednisone for Treatment of Metastatic Castration-Resistant Prostate Cancer and SPOP Gene Mutations — TERMINATED · PHASE2
• Study of PSMA-targeted Therapy and Androgen Receptor Suppression in Low-volume Metastatic ProstatE Cancer: SPARKLE Trial — NOT_YET_RECRUITING · PHASE2
• A Study To Evaluate Hypofractionated Proton Therapy Or IMRT For Recurrent, Oligometastatic Prostate Cancer — ACTIVE_NOT_RECRUITING · PHASE2
• Testing the Safety of the Anti-cancer Drug, Sn-117m-DTPA, for Advanced Cancers That Have Spread to Bones — NOT_YET_RECRUITING · PHASE1
• Erdafitinib for the Treatment of Patients With Castration-Resistant Prostate Cancer — TERMINATED · PHASE2
• Antiandrogen Therapy and SBRT in Treating Patients With Recurrent, Metastatic Prostate Cancer — ACTIVE_NOT_RECRUITING · PHASE2
• A Clinical Study Evaluating The Benefit of Adding Rucaparib to Enzalutamide for Men With Metastatic Prostate Cancer That Has Become Resistant To Testosterone-Deprivation Therapy — ACTIVE_NOT_RECRUITING · PHASE3
• Treatment of Cancer-Related Bone Pain by Using Bone-Targeted Radiation-Based Therapy (Sn-117m-DTPA) in Patients With Prostate Cancer That Has Spread to Bones — TERMINATED · PHASE2
• Vidutolimod (CMP-001) in Combination With Nivolumab for the Treatment of Metastatic Castration Resistant Prostate Cancer — SUSPENDED · PHASE2
• Vudalimab (XmAb20717) in Combination With Standard of Care Treatment in Patients With Metastatic Castration Sensitive Prostate Cancer — TERMINATED · PHASE1
• Observatory of Patients With Metastatic ProstAte Adenocarcinoma That is Resistant to Castration and Multi-LinE Strategies — ACTIVE_NOT_RECRUITING
• Cyclophosphamide and Dexamethasone for the Treatment of Metastatic Castration Resistant Prostate Cancer — ACTIVE_NOT_RECRUITING · PHASE1
• Genetic and Molecular Mechanisms in Assessing Response in Patients With Prostate Cancer Receiving Enzalutamide Therapy — COMPLETED · PHASE2
• Adjuvant High-intensity Interval Training During Chemotherapy in Metastatic Prostate Cancer Patients — WITHDRAWN · NA
• Neratinib in Patients With Metastatic Castration-Resistant Prostate Cancer — WITHDRAWN · PHASE2
• Tumor Molecular Profiling in Patients With Prostate Cancer — COMPLETED
• Evaluation of PSMA Antagonist Produced by Two Different Methods — COMPLETED · PHASE1
• sEphB4-HSA in Treating Patients With Metastatic Castration-Resistant Prostate Cancer — OTHER · PHASE2

Refine this search